患有心房的患者经验与皮肤外冠状动脉干预后联合抗血栓治疗的经验
Caylie M Poirier1, Aleesa A Carter1,2, Yvonne Kwan1
1Pharmacy Department, University Health Network, Toronto, Ontario, Canada.
CJC open
|November 29, 2023
概括
在接受PCI的心房动患者中,超过三分之二的患者有未计划的抗血栓治疗修改. 这些复杂的疗法需要更好地支持患者退院后,以减少风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 心房动 (AF) 患者经常患有冠状动脉疾病,需要皮肤冠状动脉干预 (PCI).
- 加拿大指导方针建议复杂的双重或三重抗血栓治疗 (ATT) 后PCI的AF患者.
- 复杂的ATT疗法可能会导致意外修改 (UPM),增加血栓形成和出血的风险.
研究的目的:
- 描述AF和PCI组合ATT患者的结果.
- 识别ATT方案中的计划外修改 (UPM) 的频率和类型.
- 评估UPM对患者安全的影响,包括出血事件.
主要方法:
- 在PCI后接受口服抗凝剂 (OAC) 和组合ATT的AF患者的未来随访.
- 患者在PCI后的1,3,6和12个月被联系.
- 数据收集的重点是UPMs到ATT以及相关的临床结果.
主要成果:
- 68%的患者 (44/61) 经历了至少一个UPM到他们的ATT.
- 发生了105次UPM,最常见的是延长P2Y12抑制剂持续时间 (22%) 和改变乙盐酸持续时间 (22%).
- 37%的UPM涉及OAC,75%的UPM患者经历出血.
结论:
- 在接受PCI的AF患者中,很大比例的患者在他们的ATT中经历了UPM.
- 目前的ATT治疗方案的复杂性给患者和临床医生带来了重大挑战.
- 加强出院后的患者支持对于在这个人群中管理ATT至关重要.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
532
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
532
Anticoagulant Drugs: Low-Molecular-Weight Heparins
711
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
711
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
174
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Cardiac Catheterization IV: Nursing Management
25
Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...
25
Cardiac Catheterization II: Right Heart Catheterization
23
Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...
23


